title: [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
abstract: Immunochemotherapy consisting of interferon-alpha (IFN-alpha), interleukin-2 (IL-2), and gemcitabine (GEM) for metastatic renal cell carcinoma. A partial response maintained for 15 months, was obtained in one case resistant to IFN-alpha and IL-2 of para-aortic lymph node metastases (case 1). A minor response with 30% reduction of lung metastasis was obtained in one IFN-alpha resistant case, and the duration was 6 months (case 2). In one case, in contra-lateral renal metastasis, no disease progression was obtained for 6 months (case 3). One case with resistance to IFN-alpha and IL-2, and who had preoperative abnormalities of corrected serum calcium, serum c-reactive protein and hemoglobin, had progressive disease and died of cancer after 6 months (case 4). Grade 3 toxicity was noted in leucopenia (4/4), anemia (1/4), and nausea/ vomiting (1/4). Although the response duration was short, the combination immunochemotherapy consisting of IFN-alpha, IL-2 and GEM may be a promising salvage regimen for the patients with metastatic renal cell carcinoma.
authors.affiliation: Department of Urology, Akita University School of Medicine.
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Inoue
authors.forename: Chikara
authors.initials: C
authors.lastname: Ohyama
authors.forename: Shingo
authors.initials: S
authors.lastname: Hatakeyama
authors.forename: Yohei
authors.initials: Y
authors.lastname: Horikawa
authors.forename: Hisafumi
authors.initials: H
authors.lastname: Togashi
authors.forename: Norihiko
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: Shinobu
authors.initials: S
authors.lastname: Matsuura
authors.forename: Shigeru
authors.initials: S
authors.lastname: Satoh
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sato
authors.forename: Tomonori
authors.initials: T
authors.lastname: Habuchi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D000093542:Gemcitabine
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D003841:Deoxycytidine; D000093542:Gemcitabine